How I Work With My Patients on Complement Inhibitor Therapy for GA

Some patients decide to go forward with treatment and some do not, but I find it important to educate each patient about the disease process and their options.

By: Margaret Chang, MD

Retinal Physician February 7, 2025

Clinical Report: How I Work With My Patients on Complement Inhibitor Therapy for GA

Overview

This report discusses the importance of patient education regarding complement inhibitor therapy for geographic atrophy (GA). It highlights the need for shared decision-making and the potential benefits and risks associated with treatment.

Background

Geographic atrophy (GA) is a progressive condition that can lead to significant vision loss, impacting patients' quality of life. The introduction of FDA-approved intravitreal complement inhibitors offers new treatment options, yet the retina community remains divided on their use due to concerns about safety and efficacy. Understanding patient selection and treatment adherence is crucial for optimizing outcomes in this population.

Data Highlights

No numerical data provided in the source material.

Key Findings

Review and ensure all findings are directly referenced from the source material.

Clinical Implications

Suggest strategies for clinicians to effectively communicate treatment risks to patients.

Conclusion

The integration of complement inhibitors into clinical practice represents a significant advancement in the management of GA. Ongoing education and support for patients will be vital in optimizing treatment outcomes.

PentaVision

Retinal Physician